Nucleus RadioPharma expands production with new sites, FDA issues CRL to Camurus' hormone disorder drug, NHS rejects Eli Lilly's Alzheimer's drug over cost [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:

The good — Nucleus RadioPharma expands production with new sites

The bad — FDA issues CRL to Camurus' hormone disorder drug

The ugly — NHS rejects Alzheimer's drug over cost concerns